BullishWhales · Analysts · Analyst Profile
Analyst rating accuracy & track record
Judah Frommer does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 JSPRJasper Therapeutics Inc | Buy | $4.00 | Aug 2023 | +17.6% | Miss |
 ABOSAcumen Pharmaceuticals Inc | Buy | $13.00 | Aug 2023 | −73.6% | Miss |
| JSPRJasper Therapeutics Inc | Buy | $4.00 | May 2023 | +23.1% | Miss |
 ATAIATAI Life Sciences BV | Buy | $9.00 | May 2023 | −13.5% | Miss |
 CADLCandel Therapeutics Inc | Buy | $7.00 | Mar 2023 | +10.4% | Miss |
| ABOSAcumen Pharmaceuticals Inc | Buy | $13.00 | Mar 2023 | −17.1% | Miss |
| ATAIATAI Life Sciences BV | Buy | $9.00 | Mar 2023 | +13.5% | Miss |
| JSPRJasper Therapeutics Inc | Buy | $4.00 | Mar 2023 | +39.3% | Miss |
| ATAIATAI Life Sciences BV | Buy | $9.00 | Mar 2023 | +17.0% | Miss |
| JSPRJasper Therapeutics Inc | Buy | $3.00 | Jan 2023 | −59.4% | Miss |
| CADLCandel Therapeutics Inc | Buy | $8.00 | Dec 2022 | −48.5% | Miss |
| ABOSAcumen Pharmaceuticals Inc | Buy | $16.00 | Nov 2022 | −59.2% | Miss |
| JSPRJasper Therapeutics Inc | Buy | $8.00 | Jul 2022 | −32.7% | Miss |
| JSPRJasper Therapeutics Inc | Buy | $9.00 | May 2022 | −51.0% | Miss |
| ABOSAcumen Pharmaceuticals Inc | Buy | $17.00 | Mar 2022 | +8.9% | Miss |
| JSPRJasper Therapeutics Inc | Buy | $10.00 | Feb 2022 | −49.2% | Miss |
| ATAIATAI Life Sciences BV | Buy | $24.00 | Nov 2021 | −77.5% | Miss |
 PFGCPerformance Food Group Co | Buy | $39.00 | Apr 2020 | +110.3% | Hit |
 OLLIOllie's Bargain Outlet Hldg | Buy | $78.00 | Jun 2018 | +13.2% | Hit |
Go to
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.